Company intelligence / Profile preview
SpineThera
Plymouth, Minnesota, United Statesspinethera.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
SX600 demonstrated clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection in a Phase 2 trial. The product aims to provide months-long sustained release of dexamethasone with best-in-class efficacy potential. There are currently no FDA-approved drugs for epidural injection to treat lumbar radicular pain. Market research indicates strong physician interest and high anticipated adoption rates if approved.
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Injectable drugsextended-release microspheres (dexamethasone acetate)micro-suspension technology
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ProMed Pharma LLC (manufacturing partnership; ProMed acquired manufacturing assets and will manufacture SX600 under contract)
Beyond the preview
Go deeper on SpineThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpineThera.